SpaceX Investors Beware: IPOs Significantly Underperform the Market in Year 1

The article argues that SpaceX's IPO enthusiasm may be premature, citing evidence that IPO stocks often experience significant first-year drawdowns and underperform over the longer term. It highlights SpaceX's lack of profitability, with a $4.3 billion net loss in Q1 2026 against $4.7 billion in revenue, and warns that Elon Musk's volatility could add risk. The piece is essentially a cautionary view on IPO timing rather than a catalyst-driven market update.

Analysis

The market is conflating scarcity value with fundamental value. A high-profile listing can create a reflexive squeeze in the first few sessions, but the more durable setup is usually a supply overhang: insiders, early holders, and late-stage crossover funds gain a liquid exit path, which tends to cap upside once the first wave of momentum buyers is exhausted. That matters here because sentiment is already doing most of the work, while the cash-generation profile is still too weak to anchor a large, stable institutional base.

The bigger second-order issue is that any post-IPO de-rating would likely spill beyond the name itself. A weak aftermarket in a marquee space listing tends to compress valuation appetite for the entire venture/late-stage complex, especially adjacent high-multiple “story” names that trade on narrative durability rather than near-term earnings. In this setup, names like PLTR, TSLA, and even NVDA can see short-lived multiple pressure if the market shifts from scarcity bidding to scrutiny of free cash flow and governance risk.

The contrarian view is that the first drawdown may not be the tradeable edge; the better edge may be waiting for the first operational catalyst miss or lockup-related supply event. If the IPO stabilizes, it could still work over years, but the risk/reward over the next 1-3 months is asymmetric against buyers because the market is paying up before the business has demonstrated it can self-fund growth. For medium-term investors, the cleaner expression is not to short the IPO outright on day one, but to fade the enthusiasm through pairs against higher-quality profitable compounders with similar factor exposure.

Key Decisions for Investors

• Avoid buying the IPO in the first 30-60 days; wait for post-lockup supply and/or an earnings cycle before establishing any long. The expected payoff improves materially once momentum buyers and secondary sellers have cleared.
• If you want exposure to the theme, use a pair: short the IPO against a basket long of profitable mega-cap compounders like NFLX or META over a 1-3 month horizon. This isolates valuation compression risk while reducing broad factor exposure.
• Tactically fade speculative semis/software beta by trimming PLTR and TSLA on strength if the IPO keeps squeezing. Both names are likely to feel multiple pressure if the market reassesses premium-growth valuations.
• For event-driven books, consider a small options structure: sell near-dated calls / buy farther-dated puts on the IPO once implied vol settles. The setup is favorable if first-quarter enthusiasm is strong but fundamentals remain unproven.
• Do not chase NVDA on sympathy strength from the IPO narrative; if anything, use any tech exuberance to take profits into a move, since the risk is sector multiple compression rather than fundamental contagion.